Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9850277 | SERVIER | Therapeutically active compositions and their methods of use |
Jan, 2033
(9 years from now) | |
US9474779 | SERVIER | Therapeutically active compositions and their methods of use |
Aug, 2033
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10610125 | SERVIER | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(6 years from now) | |
US10717764 | SERVIER | Therapeutically active compounds and their methods of use |
Jan, 2033
(9 years from now) | |
US10799490 | SERVIER | Pharmaceutical compositions of therapeutically active compounds |
Mar, 2035
(11 years from now) | |
US10449184 | SERVIER | Pharmaceutical compositions of therapeutically active compounds |
Mar, 2035
(11 years from now) | |
US9968595 | SERVIER | Pharmaceutical compositions of therapeutically active compounds |
Mar, 2035
(11 years from now) | |
US10653710 | SERVIER | Combination therapy for treating malignancies |
Oct, 2036
(13 years from now) | |
US10980788 | SERVIER | Therapy for treating malignancies |
Jun, 2039
(15 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 20, 2023 |
Orphan Drug Exclusivity (ODE) | Aug 25, 2028 |
New Indication (I) | May 25, 2025 |
Drugs and Companies using IVOSIDENIB ingredient
NCE-1 date: 2022-07-20
Market Authorisation Date: 20 July, 2018
Treatment: A method of treating a cancer characterized by an idh1 mutation where the cancer is relapsed or refractory acute myeloid leukemia (aml) and where the mutant idh1 has the ability to convert alpha-ketog...
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic